Fluvastatin downregulates VEGF-A expression in TNF-α-induced retinal vessel tortuosity

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7423-7431

  Robinson, Remya ^a,b   Ho, Candice E H ^a   Tan, Queenie S W ^a   Luu, Chi D ^a,c   Moe, Kyaw T ^a,d   Cheung, Carol Y ^a   Wong, Tien Y ^a,b,c,e   Barathi, Veluchamy A ^a  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d DEPARTMENT OF CARDIOLOGY   (Singapore)

^e SINGAPORE NATIONAL EYE CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA BLOOD VESSEL; RETINA DISEASE; RETINAL VESSEL TORTUOSITY; STAINING; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; DOWN REGULATION; DRUG EFFECT; EYE MALFORMATION; FLUORESCENT ANTIBODY TECHNIQUE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BLOTTING, WESTERN; DOWN-REGULATION; ELECTRORETINOGRAPHY; EYE ABNORMALITIES; FATTY ACIDS, MONOUNSATURATED; FLUORESCEIN ANGIOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL DISEASES; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856395563     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7912     Document Type: Article

References (69)

1. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications. 2008;22:309-316.
2. Huang H, Gandhi JK, Zhong X, et al. TNF-α is required for late BRB breakdown in diabetic retinopathy and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011;52:1336-1344.
3. Cousins SW, Diego GE, Csaky KG. Monocyte activation in patients with age-related macular degeneration, a biomarker of risk for choroidal neovascularization? Arch Ophthalmol. 2004;122:1013-1018.
4. Jasielskaa M, Semkovaa I, Shia X, et al. Differential role of tumor necrosis factor (TNF) receptors in the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51:3874-3883.
5. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20:155-157.
6. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis, Mol Cell Biol. 1997;17:4015-4023.
7. Kociok N, Radetzky S, Krohne TU, et al. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47: 5057-5065.
8. Behl Y, Krothapalli PT, DiPiazza DA, et al. Diabetes-enhanced tumor necrosis factor-_ production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008;172:1411-1418.
9. Lichtlen P, Lam TT, Nork MT, et al. Relative contribution of VEGF and TNF-α in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci. 2010;51:4738-4745.
10. Gardiner TA, Gibson DS, de Gooyer TE, et al. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol. 2005;166:637-644.
11. Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retinal Eye Res. 2008;27:608-621.
12. Vinores SA, Xiao WH, Shen JK, Campochiaro PA. TNF-α is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol. 2007;182:73-79.
13. Arif S, Cox P, Afzali B, et al. Anti-TNFα therapy-killing two birds with one stone? Lancet. 2010;375:2278.
14. Truong A, Wong TY, Khachigian LM. Emerging therapeutic approaches in the management of retinal angiogenesis and edema. J Cell Mol Med. 2011;89:343-361.
15. Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915-922.
16. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90: 1542-1547.
17. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
18. Wong TY. Retinal-vein occlusion. N Engl J Med. 2011;364:979.
19. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004;18:805-815.
20. Bartoli M, Al-Shabrawey M, Labazi M, et al. HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2009;50: 4934-4940.
21. Zheng Z, Chen H, Wang H, et al. Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor αcoactivator 1α. Diabetes. 2010;59:2315-2325.
22. Medina RJ, O'Neill CL, Devine AB, Gardiner TA, Stitt AW. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One. 2008;3:e2584.
23. Matsuki A, Nozawa T, Igarashi N, et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J. 2010;74(3):468-475.
24. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23:729-736.
25. Haak E, Abletshauser C, Weber S, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis. 2001;155:395-401.
26. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999;57:583-606.
27. Hussein O, Schlezinger S, Rosenblat M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 1997;128:11-18.
28. Skogastierna C, Luksha L, Kublickiene K, et al. Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels. 2011 Jan 7. [Epub ahead of print].
29. Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes. 2001;109:181-183.
30. Cheung BMY. Statins for people with diabetes. Lancet. 2008;371: 94-95.
31. Wong TY, Rogers SL. Statins and age-related macular degeneration: time for a randomized controlled trial? Am J Ophthalmol. 2007;144:117-119.
32. Moe KT, Yin NO, Naylynn TM, et al. Nox2 and Nox4 mediate tumor necrosis factor-alpha-induced ventricular remodeling in mice. J Cell Mol Med. 2011 Jan 20. doi:10.1111/j.1582-4934.2011.01261.x. [Epub ahead of print].
33. Igawa A, Inoue H, Chan-Ling T. Glial, vascular and neuronal cytogenesis in whole-mounted cat retina. Microsc Res Tech. 1997;36: 1-16.
34. Bayer AU, Neuhardt T, May AC, et al. Retinal morphology and ERG response in the DBA/2NNia mouse model of angle-closure glaucoma. Invest Ophthalmol Vis Sci. 2001;42:1258-1265.
35. Claybon A, Bishop, AJR. Dissection of a mouse eye for a whole mount of the retinal pigment epithelium. J Vis Exp. 2011;27:2563.
36. Brink N, Szamel M, Young AR, Wittern KP, Bergemann J. Comparative quantification of IL-1, IL-10, IL-10R, TNF and IL-7 mRNA levels in UV irradiated human skin in vivo. Inflamm Res. 2000;49:290-296.
37. Zhang B, Ma JX. Ocular retinopathies and clinical control of angiogenesis. Ther Angiogenesis Vasc Dis. 2011:27-65.
38. Cheung CY, Zheng Y, Hsu W, et al. Retinal vascular tortuosity, blood pressure, and cardiovascular risk factors. Ophthalmology. 2011;118(5):812-818.
39. Sasongko MB, Wang JJ, Donaghue KC, et al. Alterations in retinal microvascular geometry in young type 1 diabetes. Diabetes Care. 2010;33:1331-1336.
40. Benitez-Aguirre P, Craig ME, Sasongko MB, et al. Retinal vascular geometry predicts incident retinopathy in young persons with type 1 diabetes: a prospective longitudinal study from adolescence. Diabetes Care. 2011;34(7):1622-1627.
41. Dougherty G, Johnson MJ, Wiers MD. Measurement of retinal vascular tortuosity and its application to retinal pathologies. Med Biol Eng Comput. 2010;48:87-95.
42. Hart WE, Goldbaum M, Kube P, Nelson MR. Measurement and classification of retinal vascular tortuosity. Int J Med Informatics. 1999;53:239-252.
43. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987;84:5277-5281.
44. Machida S, Kondo M, Jamison JA, et al. P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. Invest Ophthalmol Vis Sci. 2000;41:3200-3209.
45. Bui BV, Fortune B. Ganglion cell contributions to the rat full field electroretinogram. J Physiol. 2004;555:153-173.
46. Berger S, Savitz SI, Nijhawan S, et al. Deleterious role of TNF-α in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2008;49:3605-3610.
47. Krempler K, Schmeer CW, Isenmann S, Witte OW, Löwel S. Simvastatin improves retinal ganglion cell survival and spatial vision after acute retinal ischemia/reperfusion in mice. Invest Ophthalmol Vis Sci. 2011;52:2606-2618.
48. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
49. Munaut C, Lorquet S, Pequeux C, et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod. 2008;23:1407-1415.
50. Frank RN. The Optic UK Lecture: bench-to-bedside adventures of a diabetes researcher: results past, results present. Eye. 2011;25: 331-341.
51. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: possible roles of SP-1. J Biol Chem. 1996;271:28220-28228.
52. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP, relevance to plus disease. Invest Ophthalmol Vis Sci. 2008;49: 3107-3114.
53. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem. 1998;273:22128-22135.
54. Tsuchihashi S, Ke B, Kaldas F, et al. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006;168:695-705.
55. Nabors LB, Suswam E, Huang Y, et al. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Canc Res. 2003;63:4181-4187.
56. Hangai M, He S, Hoffmann S, et al. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol. 2006;171:45-56.
57. Benjamin L. Glucose, VEGF-A and diabetic complications. Am J Pathol. 2001;158:1181-1184.
58. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90:737-744.
59. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739-745.
60. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17:1521-1526.
61. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3231-3238.
62. Li J, Wang JJ, Chen D, et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res. 2009;89:71-78.
63. Vincent L, Soria C, Mirshahi F, et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol. 2002;22:623-629.
64. Giurgea AG, Christian M, Thomas M, et al. Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol. 2006;47:30-36.
65. Blann AD, Belgore FM, Constans J, Conri C, Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol. 2001;87:1160-1163.
66. Li J, Wang JJ, Yu Q. Inhibition of reactive oxygen species by lovastatin down-regulates VEGF expression and ameliorates bloodretinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010;59:1528-1538.
67. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci. 2008;49: 3107-3114.
68. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6:511-524.
69. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167:599-607.